Blog

Sekisui XenoTech Named Best for Drug Candidate Evaluations 2019, Leading Providers of Pharmaceuticals Safety Testing

Author: Michael Millhollen Posted: 12 August 2019

SEKISUI XenoTech has been named the Best for Drug Candidate Evaluations and was recognized for leadership in Pharmaceutical Safety Testing in the 2019 International Lifesciences Awards...

Read more

In Vivo ADME: What You Need and Why You Need It

Author: Madison Knapp, Satoshi Ito Posted: 22 July 2019

Are you in need of in vivo studies to support your IND application but unsure where to start? This blog post out outlines foundational in vivo ADME steps to make your submission package more compelling; cover all your bases with staple absorption, distribution, metabolism, and excretion studies performed by the experts and learn more about timing supplemental studies earlier to avoid late-stage failure and the high expense of conducting critical ADME studies late in development...

Read more

The Story of Us

Author: Madison Knapp, Satoshi Ito Posted: 01 July 2019

This year at SEKISUI XenoTech we celebrate our 25th birthday, and our Japan branch turns 64! Read about our journey from a small academic research lab to the trusted global Contract Research Organization we are today, as well as our sister lab's path to becoming the top ADME CRO in Japan...

Read more

Transporters of Emerging Importance in Drug Development: Beyond the Guidance Documents

Author: Madison Knapp, Dr. Brian Ogilvie Posted: 25 June 2019

In May, Dr. Brian Ogilvie gave a webinar presentation titled “Transporters of Emerging Importance in Drug Development: Beyond the Guidance Documents.” Read about key takeaways from the presentation: transporters discussed in most recent FDA and ITC publications, a case study examining effects of OCT1 polymorphisms on sumatriptan AUC, the Extended Clearance Classification System, and consideration of transporters involved in atypical routes of administration...

Read more

Make the Most of Your Media

Author: Madison Knapp, Dr. Chris Bohl Posted: 19 June 2019

Getting reliable, reproducible results from studies using hepatocytes as a model system for drug metabolism is in part dependent on how well you store and handle the cells. Hepatocytes require more finesse than other cell types, and some considerations and precautions in handling might not be obvious to scientists that are new to performing studies using cryopreserved, primary hepatocytes, but have experience with cell lines. Additionally, making the right choices with respect to media is key to seeing the best results in viability, attachment, and culture life of your cells. Here we discuss some tips for handling hepatocytes and making the most of your media...

Read more

In Vitro Induction Studies: Elements of Design and Important Considerations in Data Analysis

Author: Madison Knapp, Rebecca Campbell, Dr. Joanna Barbara Posted: 13 May 2019

Enzyme Induction studies provide insight to a compound’s potential for DDI (drug-drug interaction) and is a required component for an IND submission. Induction potential is informed by testing a compound’s effects on cytochrome P450 (CYP) enzymes representative of three major receptor pathways involved in expression of drug metabolizing enzymes and transporters. In a webinar in April of 2019, Dr. Joanna Barbara addressed frequently asked questions, important study design considerations, and interpretation of study results, discussed here...

Read more

Official PMDA English Translation

Author: Dr. Brian Ogilvie, Madison Knapp Posted: 07 May 2019

The Japanese regulatory agent PMDA (Pharmaceuticals and Medical Devices Agency) recently published an official English translation of their final Drug Interaction Guideline document which describes recommended approaches by which new drug entities should be evaluated for drug-drug interaction potential prior to (or concurrently with) clinical trials and market entry in Japan. The PMDA made a correction to one legend in the final guideline. Read more about the differences from the translation of the draft document...

Read more

Quality Control is What Makes the Comprehensive Collection of Cell Lines from JCRB Among the Highest Regarded and Most Widely Distributed in the World

Author: Dr. Arihiro Kohara, Kimiho Yamada, Madison Knapp Posted: 23 April 2019

We are proud to be the exclusive distributor in North America and Europe for the Japanese Collection of Research Bioresources, a cell bank with over a thousand unique cell lines used in research labs worldwide. Of utmost importance to JCRB is quality assurance, from acquisition through storage and distribution. Read more about the methods JCRB employs to maintain high standards in quality and care for their cell lines…

Read more

Minding Your Binding: Plasma Protein Binding Potential Study Now Available at Our US and Japan Labs

Author: Madison Knapp, Andrea Wolff, Dr. Joanna Barbara Posted: 15 April 2019

Plasma Brotein Binding potential is an important part of safety considerations for a drug candidate, and data can affect dosing considerations in clinical trials. PPB studies, now available on our KC campus, use Rapid Equilibrium Dialysis to determine fraction unbound so you can reliably measure free drug concentration for therapeutic effect. Read more about the features and benefits of this updated service...

Read more

Studies in Japan: Easier & More Beneficial than You Might Think

Author: Madison Knapp Posted: 08 April 2019

The idea of sending compounds to labs outside the country may be daunting, but partnering with SEKISUI XenoTech makes it easy. Our US lab is well-known for unparalleled experience in quality in vitro ADME/DMPK/DDI studies and complementary products, but did you know that our Tokai campus is the number one market share holder in ADME studies in Japan?

Read more

Can Interactions Between Therapeutic Proteins and Small Molecule Drugs Be Evaluated In Vitro?

Author: Greg Loewen, Dr. Maciej Czerwinski Posted: 04 April 2019

Even with the rise of biologics, small molecules make up most of prescribed drugs around the world — how do they interact with large molecule therapies like therapeutic proteins?

Read more

New Liver Tissue Microarrays Available – What Would Benefit Your Research?

Author: Madison Knapp, Dr. Maciej Czerwinski Posted: 02 April 2019

Liver disease research is expanding, and researchers need the best available materials with which to expand knowledge in this area. SEKISUI XenoTech offers a variety of tissue microarrays for use in applied and academic research, and has conducted studies utilizing a newly available pediatric array to advance understanding in hyaluronan deposition and CYP activity in children affected by liver dysfunction...

Read more

Disease-State Test Systems

Author: Dr. Chris Bohl, Michael Millhollen Posted: 13 January 2019

Sekisui XenoTech has been working with and supplying reagents for the pre-clinical ADME field for well over two decades. Years of acquiring and banking human liver tissues for the production of hepatic subcellular fractions and hepatocytes has allowed us to be able to identify and produce interesting and novel hepatic disease state test systems for research groups. These test systems form the basis for our Research Biobank. We also partnered with the National Institute of Biomedical Innovation to distribute the Japanese Collection of Research Bioresources (JCRB) Cell Bank’s extensive selection of cell lines to North America and Europe...

Read more

Important Considerations for the Conduct of In Vitro Drug Transporter Assays

Author: Greg Loewen, Andrea Wolff, Michael Millhollen Posted: 11 January 2019

Not only can drug transporters affect the absorption and excretion of drugs, they can be involved in pharmacokinetic-based drug-drug interactions (DDI), impacting distribution into tissues as well as the overall exposure of the drug. As a result, regulatory bodies such as the FDA, EMA and PMDA recommend studying the potential of NCEs to be inhibitors or substrates of drug transporters in vitro in order to better understand the ADME and DDI potential of drugs and help determine if clinical studies should be performed. The design and scope of in vitro transporter studies can vary depending on the physicochemical properties and major route(s) of excretion of the drug and should be considered when designing and performing in vitro studies that will support a new drug application (NDA) or decisions to run clinical DDI studies...

Read more

5 Keys to Set Your Contract Research Organization (CRO) Collaboration Up for Success

Author: Kelsey Pigg, Michael Millhollen Posted: 07 January 2019

Over the past 25 years of performing ADME/DMPK/DDI contract research, we’ve learned some key strategies to maximize the efficiency and effectiveness of our clients’ studies. Here are a few critical considerations that will help you ensure that your studies are completed on time and deliver the most accurate, relevant data...

Read more

Holiday CSR Activities

Author: Michael Millhollen, Deja Coffin Posted: 26 December 2018

Sekisui understands that a better future starts with our actions today, and encourages its global family to remain focused on contributing to society through our business activities. This includes a commitment to environmental stewardship, our customers, diversity in human resources and giving back to our communities. This holiday season, Sekisui XenoTech employees participated in numerous efforts, including a Harvesters Food Drive, Angel Tree and volunteer work...

Read more

2017 FDA Guidance: Many In Vitro DDI Evaluations Should Precede FIH Studies

Author: Dr. Brian Ogilvie, Andrea Wolff Posted: 06 December 2018

While the 2017 FDA DDI guidance contains many important changes, the earlier timing of drug-drug interaction studies is perhaps the most daunting. This is especially true for developers with drugs in the later clinical stages. Does this guidance mean sponsors are required to backtrack, and if so, how far? This article outlines the implications of these new timing requirements and best practices for negotiating them efficiently and effectively moving forward...

Read more

SEKISUI Continues Environmental Awareness and Sustainability Efforts

Author: Michael Millhollen Posted: 03 December 2018

SEKISUI participated in the Natural Capital Week in Paris and “Forum on Decarbonizing the Economy” panel while Sekisui XenoTech made progress towards our sustainability goal of zero emissions and zero landfill...

Read more

Coverage from the October 2018 PBSS DDI Workshop

Author: Greg Loewen, Michael Millhollen Posted: 05 November 2018

The Pharmaceutical and BioScience Society (PBSS) hosted the workshop “Drug-Drug Interactions: Update on Risk Assessment, Clinical Evaluation and Regulatory Requirements” on October 16 at the Crowne Plaza Hotel in Foster City, CA. The workshop was well attended and provided a great update on DDI potential...

Read more

October Presentations on In Vitro Effects of Biologics on CYP Enzymes and Regulatory DDI Guidances

Author: Michael Millhollen Posted: 26 October 2018

Dr. Brian Ogilvie presented on In vitro Direct and Cytokine-Mediated Effects of Therapeutic Peptides and other Biologics on CYP Enzymes at the Peptide ADME Discussion Group Workshop and a Comparison Between the US FDA, EMA and Japan PMDA In Vitro DDI Guidances: Are we Closer to Harmonization? at the DMDG-SPS Joint Meeting in Gothenburg, Sweden...

Read more

To GLP, or Not To GLP?

Author: Scott Hickman, Dr. Brian Ogilvie, Tim Patterson Posted: 05 October 2018

In vitro drug interaction studies do not necessarily need to be performed under GLP conditions. To learn more — and probably save time and considerable money — read this article...

Read more

New Recommendation: Evaluate NMEs for OCT1 Transporter-Mediated DDI Potential

Author: Andrea Wolff, Brian Ogilvie Posted: 01 October 2018

Patient-to-patient variability in the activity of liver transporter OCT1 turns out to be a huge factor in the therapeutic activity and clearance of several commonly prescribed drugs. Dr. Brian Ogilvie presented a case for in vitro OCT1 transporter studies in 2017 based on the effects of polymorphisms on sumatriptan, and now the International Transporter Consortium (ITC) is weighing in. Learn some of the highlights of their August 2018 recommendations (like why OCT1 studies matter)...

Read more

Cypex Expands Portfolio of Recombinant Enzymes

Author: Scott Hickman Posted: 18 September 2018

Cypex offers an extensive portfolio of Cytochrome P450 (CYP) enzymes (Bactosomes) prepared using their patented technique involving expression in E. coli, rather than in insect cells. In addition to humanmouse, monkey and rat enzymes, Cypex has introduced several dog, insect and pig CYPs. These recombinant enzymes, available as preparations with activity levels similar to those found in vivo, or as preparations with a high activity, are ideal test systems for preclinical reaction phenotyping and inhibition studies...

Read more

New Rodent, Monkey CryostaX Hepatocytes Featured in Industry News

Author: Michael Millhollen Posted: 13 September 2018

Following Sekisui XenoTech's announcement Sekisui XenoTech Adds Monkey, Rodent Hepatocytes to Patented CryostaX Product Line, Anticipates the End of Traditionally Cryopreserved Hepatocytes, various industry publications have posted coverage...

Read more

Challenges & Solutions in Today’s In Vitro Transporter Research

Author: Dr. Joanna Barbara, Michael Millhollen Posted: 30 August 2018

In vitro drug transport assays are performed throughout drug development and range from simple permeability screens to kinetic assessments in complex assay formats. Sometimes interpreting transporter assay results is straightforward, and sometimes applying the data to make smart decisions is challenging...

Read more

Sekisui XenoTech Named Best Global CRO 2018; Recognised Leaders in Pharmaceutical Safety Testing 2018

Author: Michael Millhollen Posted: 24 August 2018

Sekisui XenoTech has been named the Best Global CRO and was recognized for leadership in Pharmaceutical Safety Testing in the 2018 International Lifesciences Awards...

Read more

Response to FDA Framework for Assessment of Drug-Drug Interactions for Therapeutic Proteins RFI and Comments

Author: Michael Millhollen Posted: 06 August 2018

In July, Drs. Maciej Czerwinski, Director of Consulting, and Brian Ogilvie, Vice President of Scientific Consulting, submitted Sekisui XenoTech’s comments in response to the Food and Drug Administration (FDA) public docket to assist with its development of a policy/guidance document on the assessment of drug-drug interactions (DDIs) for therapeutic proteins (TPs)...

Read more

IQ Induction Working Group Publishes Recommendations for Data Interpretation of In Vitro Induction - Focus on CYP3A4 mRNA

Author: Scott Hickman, Dr. Brian Ogilvie Posted: 13 July 2018

Sekisui XenoTech made contributions to the June 29th paper entitled, “Considerations from the IQ Induction Working Group in Response to Drug-Drug Interaction Guidances from Regulatory Agencies: Focus on CYP3A4 mRNA in vitro response thresholds, variability, and clinical relevance.” This paper, prepared by the IQ Induction Working Group of The International Consortium for Innovation & Quality in Pharmaceutical Development (IQ) and found in the journal Drug Metabolism and Disposition, provides recommendations that do not supersede any regulatory guidance at this time, but do guide pharmaceutical companies on how to conduct CYP induction studies...

Read more

New Guidance on Bioanalytical Services

Author: Seema Muranjan, Scott Hickman Posted: 06 July 2018

On May 24, 2018, the US Food and Drug Administration (FDA) released new Bioanalytical Method Validation Guidance for Industry. Sekisui XenoTech’s approach to method validation is based on this bioanalytical guidance document, along with the most recent European Medicines Agency (EMA) 2011 Guideline on bioanalytical method validation...

Read more

No-Cost, On-Demand Primary Human Hepatocyte Pooling Using CryostaX Pellets

Author: Dr. Chris Bohl, Michael Millhollen Posted: 15 June 2018

CryostaX® hepatocytes are created using a patented process that produces unique single-donor cell pellets, allowing unprecedented ease and versatility for custom pooling...

Read more

AAPS-FDA Drug Transporters in ADME Workshop Recap

Author: Greg Loewen, Michael Millhollen Posted: 30 May 2018

The AAPS and FDA co-sponsored the workshop “Drug Transporters in ADME: From the Bench to the Bedside.” There were 26 presentations covering numerous aspects of transporter science as well as poster sessions...

Read more

NADPH RapidStart regeneration system for extended metabolism

Author: Isabelle Nobiron, tebu-bio Posted: 30 May 2018

A post from our EU partner, tebu-bio, on NADPH regeneration for ADME-Tox studies using recombinant CYPs (incl. bactosomes) or cellular fractions (Microsomes, S9)...

Read more

In Vitro DDI Regulatory Guidance Reference Poster

Author: Michael Millhollen Posted: 29 May 2018

Download Sekisui XenoTech’s poster outlining the current FDA, EMA & PMDA guidance experimental details, equations, cut-off values, etc. for in vitro drug-drug interaction studies...

Read more

Maximize Metabolic Activities by Limiting Hepatocyte Cryoinjury

Author: Dr. Chris Bohl, Michael Millhollen Posted: 01 May 2018

Cryopreservation and thawing of primary hepatocytes causes inherent damage to the cells. However, utilizing a single-freeze method for pooling donors is shown to preserve higher metabolic activity...

Read more

Assess catabolic stability of biologics & ADCs with Lysosomes – Characterized test systems

Author: Isabelle Nobiron, tebu-bio Posted: 30 April 2018

A post from our EU partner, tebu-bio, on the characterization of isolated human liver lysosomes, and validating them as test systems for in vitro assessment of catabolic stability of biologics drugs entering the cell by the endosomal–lysosomal pathway...

Read more

No More Water Baths! Simplify Hepatocyte Thaws and Eliminate Contamination

Author: Dr. Chris Bohl, Michael Millhollen Posted: 03 April 2018

By eliminating the need for water baths, a significant source of tissue culture contamination can be removed, efficiency is increased and performance variability is decreased...

Read more

Sekisui XenoTech Adds US and Japanese Support for MATE1 and MATE2-K Drug Transporter Studies

Author: Michael Millhollen Posted: 02 April 2018

Sekisui XenoTech now offers MATE1 and MATE2-K drug transporter evaluation services at our research labs in the USA as well as Japan!

Read more

Sekisui Medical Celebrates its 10th Anniversary

Author: Michael Millhollen Posted: 01 April 2018

It's been 10 years since Sekisui Medical Co., Ltd. was established, the same year XenoTech, LLC was acquired...

Read more

Sekisui XenoTech Named Best In Vitro Drug Metabolism Studies Provider 2018

Author: Michael Millhollen Posted: 27 March 2018

Sekisui XenoTech has been named the Best In Vitro Drug Metabolism Studies Provider in the 2018 Biotechnology Awards. “This awards programme recognises the hard work and dedication of the firms, and the individuals behind them, that are driving innovation in this vital market. It has been my honour to recognise these dedicated professionals and I would like to wish them the very best of fortunes for the future...”

Read more

Choosing a Relevant Small Animal Model for Pharmacokinetic or Toxicity Studies

Author: Dr. Chris Bohl Posted: 01 March 2018

Choosing the most suitable small animal model is crucial for pharmacokinetic and/or toxicology studies in order to get usable, relevant data. Due to potential species-dependent variability in candidate drug metabolism, the decision of which small animal model to utilize may not always be obvious...

Read more

Recombinant CYP Bactosomes: versatile formats for many ADME applications

Author: Isabelle Nobiron, tebu-bio Posted: 25 February 2018

A post from our EU partner, tebu-bio, on Recombinant CYPs, which are commonly used in ADME-Tox studies as in vitro tools, mostly for reaction phenotyping, enzyme inhibition screening, clearance and metabolite ID...

Read more

Insects and Cattle and Sheep, Oh My!

Author: Aaron Hilgedick, Michael Millhollen Posted: 15 February 2018

Over the past two decades, we’ve received a lot of interesting requests for custom tissue preparations here at Sekisui XenoTech. Read about some of the unique species, tissues and cellular preparations as well as characterization assays that we’ve performed...

Read more

Sekisui Named in the 2018 Global 100 World’s Most Sustainable Corporations

Author: Michael Millhollen Posted: 26 January 2018

Our parent company has been selected as one of the 2018 Global 100 Most Sustainable Corporations in the World index (2018 Global 100)!

Read more

Sekisui XenoTech Hiring and Growing to Meet Customer Demand

Author: Michael Millhollen Posted: 08 January 2018

We hired a record number of new staff over the past year in order to meet current demand for our products and services…

Read more

What to Do with Microsome Stable, Low-Turnover Compounds

Author: Dr. Chris Bohl Posted: 07 December 2017

Compounds that exhibit high metabolic stability in hepatocytes and subcellular fractions can be a challenge for ADME scientists. These in vitro drug metabolism test systems are easy to source and use at the bench, and the methods for xenobiotic metabolism in these matrices are largely standardized and accepted by the scientific community, but they are limited to a 4-6 hour window of time when they are metabolically active and can generate quality data. There have been many interesting advances in the field to address these constraints, though...

Read more

Sekisui XenoTech Featured in the Fall Issue of NewsWave

Author: Michael Millhollen Posted: 15 November 2017

Read about our academic roots, how our path led us to being a global contract research organization, and where our path is taking us...

Read more

Initial Impressions of the new Draft FDA DDI Guidance Documents from Sekisui XenoTech

Author: Dr. Brian Ogilvie, Michael Millhollen Posted: 26 October 2017

The FDA has released its new draft guidance for DDI studies. View the documents and learn more about this important release...

Read more

Hepatosure Hepatocytes: the largest donor pool for your DMPK applications

Author: Isabelle Nobiron, tebu-bio Posted: 18 October 2017

HepatoSure® is a pool of human hepatocytes designed to facilitate your DMPK applications. HepatoSure® is best suited for both discovery and development of ADME-Tox study assays where generation and comparison of data is required. Let’s take a closer look...

Read more

Further Research on the Drug-Drug Interaction Between Gemfibrozil and Repaglinide Presented

Author: Michael Millhollen Posted: 27 September 2017

Sekisui XenoTech scientists previously established a gemfibrozil/repaglinide DDI resulting in increased repaglinide and metabolite plasma exposure and a vectoral shift in elimination pathways from biliary to urinary excretion following administration of gemfibrozil in male Sprague-Dawley rats. In that study, negligible effects on liver enzyme activity were observed following gemfibrozil treatment, suggesting that the DDI in rats was unlikely to be caused by P450 or UGT inhibition. In the present study, the potential role of uptake transporter proteins in the interaction was explored in vitro...

Read more

Cold Storage Solution Linked to Lower AO, XO Activity

Author: Michael Millhollen Posted: 22 August 2017

Allopurinol, UW cold storage solution has been shown to reduce aldehyde oxidase and xanthine oxidase activity in common human liver test systems for in vitro drug metabolism studies…

Read more

Considerations in Response to Drug-Drug Interaction Guidances

Author: Michael Millhollen Posted: 17 August 2017

Sekisui XenoTech scientists contributed to the published considerations from the IQ Induction Working Group in response to drug-drug interaction guidances from regulatory agencies...

Read more

URI Drug Transporters Workshop Presentations

Author: Michael Millhollen Posted: 11 August 2017

If you couldn't make it to The University of Rhode Island College of Pharmacy's 5th Annual Transporters in Drug Discovery and Development: Driving Knowledge from Laboratory to Label (TDDD 2017), you can still view our presentations...

Read more

New Division Directors for Core Services and Services Logistics Appointed

Author: Michael Millhollen Posted: 01 August 2017

Following the promotion of Dr. Joanna Barbara, Ph.D., to Vice President of Scientific Operations, Dr. Etsuko Usuki, Ph.D., has been promoted to the position of Division Director for Sekisui XenoTech's Core Services. Andrea Wolff has also been appointed to the newly created position of Division Director for Sekisui XenoTech's Services Logistics...

Read more

Sekisui XenoTech's Analytical Services Department Adds New Instrumentation

Author: Michael Millhollen Posted: 17 July 2017

Sekisui XenoTech's Analytical Services lab provides researchers with custom method development and method validation, dose solution analysis, in vitro and in vivo metabolite profiling studies, small-molecule non-GLP bioanalysis and more utilizing specialized equipment, including a Waters Xevo TQ-S mass spectrometer and Xevo G2-XS quadrupole time-of-flight (QTof) mass spectrometer...

Read more

Considerations When Studying Esterase Activities in the Intestine

Author: Dr. Chris Bohl, Michael Millhollen Posted: 11 July 2017

First-pass metabolism in the gut is commonly associated with CYP450 and UGT enzymes, however, it may be important for you to consider the impact of intestinal esterases on your compound. Utilizing a PMSF-free preparation for your test system maintains high levels of esterase activity to ensure reliable experimental results, but is less useful for CYP450 metabolism studies due to low activities...

Read more

UGT activities, concomitant drugs, and DDI

Author: Michael Millhollen Posted: 20 June 2017

Do you have questions or concerns about how your compound may affect UGT induction and/or inhibition when combined with other therapeutic regiments? We can help address those concerns...

Read more

New range of Pig P450s Bactosomes

Author: Isabelle Nobiron, tebu-bio Posted: 19 June 2017

If you are looking for enzymatic in vitro tools for drug metabolismreaction phenotyping or metabolite generation using a pig model, you may find these newly released Pig Bactosomes from Cypex of interest...

Read more

Metabolite production made fast and easy – BMO Kits

Author: Isabelle Nobiron, tebu-bio Posted: 14 June 2017

Metabolite characterization can be a lengthy process making your in vitro drug testing time consuming and expensive. Whether you are working on phase I or phase II metabolic enzymatic reactions, take a look at these BMO kits which can help you speed up this characterization process...

Read more

New Liver Disease Resource & Other Research Biobank News

Author: Dr. Maciej Czerwinski, Michael Millhollen Posted: 26 May 2017

Download the new FLD progression infographic: Characteristics of Normal and Fatty Liver Disease Tissues, or read about the new gallbladder tissue as well as liver tissue samples from donors diagnosed with steatosis and steatohepatitis along with additional details on NASH and Diabetic donors...

Read more

Big Hepatocytes News!

Author: Michael Millhollen Posted: 10 May 2017

Sekisui XenoTech was issued U.S. Patent No. 9,642,355 for the “CRYOPRESERVATION OF CELLS AND SUBCELLULAR FRACTIONS” and enhanced its catalog of hepatocyte offerings...

Read more

New VP of Scientific Operations and VP of Scientific Consulting Appointed

Author: Michael Millhollen Posted: 04 May 2017

Sekisui XenoTech has appointed Dr. Joanna Barbara as Vice President of Scientific Operations and Dr. Brian Ogilvie as Vice President of Scientific Consulting...

Read more

New Lysosome Catabolism Protocol and Tech Tips

Author: Dr. Chris Bohl, Michael Millhollen Posted: 17 April 2017

New guide available: IgG Catabolism Protocol & Lysosome / Tritosome Technical Tips… 

Read more

Sekisui XenoTech Adds New Drug Transporters to Portfolio

Author: Michael Millhollen Posted: 01 April 2017

Sekisui XenoTech features the most extensive selection of drug transporters and assays available in the world, and now we have added 6 more to the list...

Read more

Sekisui Turns 70 This Month!

Author: Michael Millhollen Posted: 03 March 2017

From a single plastics manufacturing plant in Japan to a diverse, multi-billion-dollar, global family which includes Sekisui XenoTech in Kansas City, Sekisui Chemical Group has positioned itself as a corporate leader in key industries and a strong advocate for environmental issues. XenoTech joined the Sekisui team in 2008 to bring focused expertise on biotransformation and preclinical development consulting to the broad range of pharmaceutical development services offered by Sekisui.

Read more

Sekisui XenoTech Named Best for Pharmaceutical Safety Testing 2017

Author: Michael Millhollen Posted: 02 March 2017

Sekisui XenoTech has been named the Best for Pharmaceutical Safety Testing in the 2017 Biotechnology Awards. “This awards programme recognises the hard work and dedication of the firms, and the individuals behind them, that are driving innovation in this vital market. It has been my honour to recognise these dedicated professionals and I would like to wish them the very best of fortunes for the future...”

Read more

Sekisui XenoTech Adds New Dermal Subcellular Fraction Test Systems

Author: Michael Millhollen Posted: 01 February 2017

Sekisui XenoTech now offers human, minipig, mouse and rat dermal microsomes or S9 fractions as in stock standard test systems for the development of safer new products delivered to or through the skin. Subcellular fractions are widely used in drug discovery and preclinical drug development to evaluate the in vitro metabolism of new therapeutics.

Read more

Pharmaceutical Outsourcing Magazine Interview Nov-Dec 2016

Author: Michael Millhollen Posted: 29 November 2016

Pharmaceutical Outsourcing Magazine interviewed Chris Bohl, PhD, Global Technical Support Manager for Sekisui XenoTech’s Products Division, on the company and what's new...

Read more

Sekisui XenoTech Standardizes Lysosomal Test Systems for Biopharmaceutical Development

Author: Dr. Chris Bohl, Michael Millhollen Posted: 05 October 2016

Sekisui XenoTech now offers hepatic human lysosomes and rat tritosomes as standard test systems. These products contain high concentrations of lysosomal degradative enzymes and constitute advantageous test systems for analysis of catabolism and/or activation for targeted biopharmaceuticals that enter cells through the endosomal-lysosomal pathway...

Read more

Sekisui XenoTech Joins Fight Against Liver Disease

Author: Dr. Maciej Czerwinski, Michael Millhollen Posted: 16 September 2016

Currently, there are no approved therapies for NASH, yet nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) affects 1-in-4 people worldwide. Research BioBank provides disease-defined liver tissue samples and hepatocytes as a convenient human model for hepatic disease research...

Read more

Sekisui XenoTech Featured on Labiotech.EU

Author: Michael Millhollen Posted: 05 July 2016

In the article, titled "Understand which transporters are involved in a drug’s absorption, distribution & excretion," Labiotech.EU's editors collaborated with our team to discuss: "How can you build the best case for a new drug application to the regulatory agencies? Preclinical studies are a crucial part in determining the pharmacokinetics of a drug – and more specifically how it is going to interact with drug transporters. So reaching out to the leading provider and consultant in this area (with strong academic roots) is the logical step at this stage of development..."

Read more

XenoTech Scientists Publish Paper, Present Research Evaluating Ketoconazole and its Alternative Clinical CYP3A4-5 Inhibitors as Inhibitors of Drug Transporters

Author: Michael Millhollen Posted: 25 April 2016

Sekisui XenoTech scientists published a paper in Drug Metabolism and Disposition evaluating Ketoconazole and its alternative clinical CYP3A4-5 inhibitors as inhibitors of drug transporters, and presented their research at a meeting of the Delaware Valley Drug Metabolism Discussion Group (DVDMDG), during a webinar earlier this month, and with a poster at the AAPS/ITC Workshop on Drug Transporters.

Read more

Sekisui XenoTech Fulfills Largest Order To Date

Author: Michael Millhollen Posted: 01 February 2016

Sekisui XenoTech recently fulfilled its largest order of human liver subcellular fractions to date. A large pharmaceutical customer ordered over 30,000 vials of microsomes, 5000 vials of S9 fractions and 5000 vials of cytosol.

Read more

XenoTech Hosts Bring Your Kids to Work Day

Author: Matt Beck Posted: 04 May 2015

XenoTech hosted "Bring your kids to work" day on April 23rd.

Read more

XenoTech Executives Take the Ice Bucket Challenge to Benefit ALS

Author: Matt Beck Posted: 22 August 2014

XenoTech employees raised over $1,400 in a single day to benefit the ALS Association. Watch the video of the Ice Bucket Challenge by clicking on the link to read more!

Read more

XenoTech Promotes Environmental Responsibility

Author: Christian Darabant Posted: 14 August 2014

XenoTech employees embrace Sekisui Environmental Week

Read more

XenoTech Company Halloween

Author: Matt Beck, Marketing Manager Posted: 01 November 2013

Happy Halloween, XenoTech style! Enjoy some pictures from this year's festivities.

Read more

Navigating the Transporter Wave of 2013: A Review of the Seven ITC Publications on Drug Transporters

Author: Greg Loewen, Principal Scientist - Drug Transport Posted: 28 August 2013

The International Transporter Consortium (ITC) issued seven papers in the July 2013 issue of Clinical Pharmacology & Therapeutics. These seven papers summarize the current understanding of transporters as related to possible drug-drug interactions (DDI). Although there is a mountain of research focusing on many aspects of drug transport such as the transport of endogenous compounds, transport regulation, characterizing transporter function, targeting transporters for disease treatment, etc. these papers outline the information most drug development companies need to know to investigate possible DDIs and properly label their compounds to prevent transporter based DDIs. Since the FDA issued the 2006 “Guidance for Industry, Drug Interaction Studies…” which described the in vitro assays suggested to predict possible P-gp related DDIs, the ITC published a white paper in 2010, the EMA issued the draft “Guideline on the Investigation of Drug Interactions” in 2010 and both the FDA and EMA published updated guidelines in 2012. The most recent guidelines described seven transporters that should be studied for possible DDIs, the in vitro assays used to study those transporters and decision trees to help decide if clinical studies were warranted to further elucidate possible DDIs. The seven papers published in July discuss the clinical importance of the MATE transporters, the clinical importance of OATP1B1 and BCRP polymorphisms, the applicability of the decision trees with some examples of compounds approved since the decision trees were published, in vitro methods used to study transporters, intercellular drug concentrations, kinetic parameters in conjunction with translational modeling, and why DDIs at the blood brain barrier are unlikely. A summary of the focus and main points of each of the seven papers can be found by clicking "Read More" below. To view our webinar on the seven papers click here

Read more